CVRx

CVRx, Inc. develops proprietary active implantable technology to treat high blood pressure and heart failure. It has developed the second generation Barostim neo, an implantable system designed to treat heart failure and hypertension. It operates through the following geographical segments: United States, Germany, and Other Countries. The company was founded by Robert S. Kieval and Tyler P. Lipschultz in August 2000 and is headquartered in Minneapolis, MN.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

CVRx reports stellar Q4 results, eyes growth opportunities in 2023

CVRx's strong performance in 2022, highlighted by revenue growth and operational advancements, sets a positive trajectory for the company. While challenges persist in European market expansion, the focus on key growth areas and strategic initiatives positions CVRx for continued success in 2023.

CVRx reports stellar Q1 performance, eyes label expansions for growth

CVRx's Q1 2023 showcased robust revenue growth, operational progress, and increased guidance for the full year. While challenges like rising expenses and inventory management exist, the company's focus on profitability, label expansions, and market expansion programs position it well for future success.

CVRx excels in Q2 with robust revenue growth and market expansion

CVRx's strong Q2 performance, revenue growth, and strategic initiatives position the company for future success in the heart failure market.
While facing challenges in clinical trial enrollment and regulatory uncertainties, CVRx's focus on market expansion and pricing optimization presents opportunities for sustained growth.
With a clear roadmap for revenue improvement, cash flow optimization, and market penetration, CVRx is poised to capitalize on the growing demand for its therapies.

CVRx reports robust Q3 performance, raises full-year revenue guidance

CVRx delivered a strong performance in Q3 2023, marked by revenue growth and operational advancements.
While facing challenges like net losses and regulatory uncertainties, the company is well-positioned for future growth.
Opportunities lie in market expansion, revenue growth, and maintaining operational efficiencies for sustained success.

CVRx posts robust Q4 earnings, eyes growth amid leadership transition

CVRx reported strong financial performance in Q4 2023, with significant revenue growth and operational achievements.
The company faces challenges in managing expenses, designing new clinical studies, and balancing growth strategies.
Opportunities lie in expanding market opportunities, engaging stakeholders for new programs, and pursuing aggressive growth strategies.
Guidance for 2024 indicates a positive outlook with revenue projections and strategic focus on growth and operational efficiency.

CVRx reports revenue growth in Q1, focuses on therapy adoption

CVRx's Q1 performance showed revenue growth but faced challenges from disruptions and increased expenses.
Strengthening market development efforts and therapy adoption are key focus areas for CVRx.
Opportunities lie in improving awareness, evidence, and access for Barostim therapy.
Navigating challenges like sales turnover and market dynamics will be crucial for CVRx's growth.

CVRx reports strong revenue growth and strategic leadership enhancements

CVRx's Q2 2024 performance showed revenue growth and strategic leadership enhancements.
While challenges like increased expenses and net losses persist, opportunities for revenue growth exist.
The company's focus on market advocacy and product development positions it for future success.

CVRx reports revenue growth and strategic focus amidst rising expenses

CVRx shows revenue growth and positive therapy outcomes but faces challenges in managing expenses. The company's financial position remains stable with a focus on strategic growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CVRx, Inc. engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It operates through the United States, Germany, and Other Countries geographical segments. The company was founded by Robert S. Kieval and Tyler P. Lipschultz in August 2001 and is headquartered in Minneapolis, MN.

MINNEAPOLIS, Nov. 20, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced that the management team will present at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, Dec. 4, 2024. The Company is scheduled to present at 3:30 PM Eastern Time the same day via webcast.

CVRx to Present at the Piper Sandler 36th Annual Healthcare Conference

CVRx's Barostim therapy shows strong clinical success and impressive revenue growth. Recent reimbursement approvals from CMS enhance Barostim's sales potential. Despite double-digit sales growth and a promising product, CVRx's path to profitability is hindered by escalating SG&A costs and potential future shareholder dilution.

CVRx: Impressive Top-Line Growth Seems Priced In

CVRx, Inc. (NASDAQ:CVRX ) Q3 2024 Earnings Conference Call October 29, 2024 4:30 PM ET Company Participants Mike Vallie - Investor Relations Kevin Hykes - President & Chief Executive Officer Jared Oasheim - Chief Financial Officer Conference Call Participants Macauley Kilbane - William Blair Rohin Patel - JPMorgan Frank Takkinen - Lake Street Capital Market Chase Knickerbocker - Craig-Hallum Capital Group Ross Osborn - Cantor Fitzgerald. Operator Welcome to CVRx Q3 2024 Earnings Call.

CVRx, Inc. (CVRX) Q3 2024 Earnings Call Transcript

CVRx (CVRX) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to loss of $0.43 per share a year ago.

CVRx (CVRX) Reports Q3 Loss, Tops Revenue Estimates

CVRx (CVRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

CVRx (CVRX) Soars 17.2%: Is Further Upside Left in the Stock?

MINNEAPOLIS, Oct. 18, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, announced today that the American Medical Association (AMA) CPT® Editorial Panel has accepted new Current Procedural Terminology (CPT) Category I codes for baroreflex activation therapy (“Barostim”) to treat the symptoms of heart failure.

CVRx announces new CPT® Category I codes for Barostim

MINNEAPOLIS, Oct. 15, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neuromodulation device for patients with cardiovascular diseases, today announced that it plans to release third quarter 2024 financial and operating results after market close on Tuesday, October 29, 2024. The Company will host a conference call to review its results at 4:30pm Eastern Time the same day.

CVRx to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call on October 29, 2024

CVRx announces the publication of positive study data for its Barostim therapy.

CVRX Stock Gains on Unveiling of Barostim's Positive Study Data

Kevin Ballinger and Mitch Hill appointed as new independent Board members Kevin Ballinger and Mitch Hill appointed as new independent Board members

CVRx Announces Appointment of Two New Board Members

NEW YORK, NY / ACCESSWIRE / August 21, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of CVRx, Inc. ("CVRx" or "the Company") (NASDAQ:CVRX). Investors who purchased CVRx securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CVRX.

CVRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into BRONSTEIN, GEWIRTZ & GROSSMAN, LLC and Encourages Clients to Contact the Firm!

NEW YORK, NY / ACCESSWIRE / August 20, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of CVRx, Inc. ("CVRx" or "the Company") (NASDAQ:CVRX). Investors who purchased CVRx securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CVRX.

CVRX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into BRONSTEIN, GEWIRTZ & GROSSMAN, LLC and Encourages Shareholders to Contact the Firm Today!

NEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of CVRx, Inc. (“CVRx” or “the Company”) (NASDAQ: CVRX). Investors who purchased CVRx securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CVRX.

CVRx, Inc. (CVRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

NEW YORK, NY / ACCESSWIRE / August 19, 2024 / Pomerantz LLP is investigating claims on behalf of investors of CVRx, Inc. ("CVRx" or the "Company") (NASDAQ:CVRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of CVRx, Inc. - CVRX

LOS ANGELES, CA / ACCESSWIRE / August 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CVRx, Inc. ("CVRx" or "the Company") (NASDAQ:CVRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Is Investigating CVRx Inc For Securities Fraud And Urging Investors To Join

NEW YORK, NY / ACCESSWIRE / August 19, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of CVRx, Inc. ("CVRx" or "the Company") (NASDAQ:CVRX). Investors who purchased CVRx securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CVRX.

CVRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into BRONSTEIN, GEWIRTZ & GROSSMAN, LLC and Encourages Shareholders to Contact the Firm Today!

LOS ANGELES, CA / ACCESSWIRE / August 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CVRx, Inc. ("CVRx" or "the Company") (NASDAQ:CVRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Is Seeking CVRx Inc Shareholders To Join Fraud Investigation

NEW YORK, NY / ACCESSWIRE / August 18, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of CVRx, Inc. ("CVRx" or "the Company") (NASDAQ:CVRX). Investors who purchased CVRx securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CVRX.

CVRX STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into BRONSTEIN, GEWIRTZ & GROSSMAN, LLC and Encourages Investors to Contact the Firm Today!

LOS ANGELES, CA / ACCESSWIRE / August 17, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CVRx, Inc. ("CVRx" or "the Company") (NASDAQ:CVRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

CVRx Inc Shareholders Can Join Fraud Investigation With The Schall Law Firm

LOS ANGELES, CA / ACCESSWIRE / August 16, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CVRx, Inc. ("CVRx" or "the Company") (NASDAQ:CVRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

CVRx Inc Investors Encouraged To Participate In Fraud Inquiry With The Schall Law Firm

NEW YORK, NY / ACCESSWIRE / August 16, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of CVRx, Inc. ("CVRx" or "the Company") (NASDAQ:CVRX). Investors who purchased CVRx securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CVRX.

CVRX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into BRONSTEIN, GEWIRTZ & GROSSMAN, LLC and Encourages Investors to Contact the Firm Today!

LOS ANGELES, CA / ACCESSWIRE / August 15, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CVRx, Inc. ("CVRx" or "the Company") (NASDAQ:CVRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

CVRx Inc Shareholders Urged To Participate In Fraud Inquiry With The Schall Law Firm

NEW YORK, NY / ACCESSWIRE / August 15, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of CVRx, Inc. ("CVRx" or "the Company") (NASDAQ:CVRX). Investors who purchased CVRx securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CVRX.

CVRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into BRONSTEIN, GEWIRTZ & GROSSMAN, LLC and Encourages Investors to Contact the Firm Today!

LOS ANGELES, CA / ACCESSWIRE / August 14, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CVRx, Inc. ("CVRx" or "the Company") (NASDAQ: CVRX ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

CVRx Inc Shareholders Invited To Join Fraud Inquiry With The Schall Law Firm

NEW YORK, NY / ACCESSWIRE / August 14, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of CVRx, Inc. ("CVRx" or "the Company") (NASDAQ:CVRX). Investors who purchased CVRx securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CVRX.

CVRX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into BRONSTEIN, GEWIRTZ & GROSSMAN, LLC and Encourages Stockholders to Contact the Firm!

News for CVRx Stock (CVRX)